Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives

Treatment of acute myeloid leukemia (AML) has improved in recent years and several new therapeutic options have been approved. Most of them include mutation-specific approaches (e.g., gilteritinib for AML patients with activating <i>FLT3</i> mutations), or are restricted to such defined...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maximilian Fleischmann, Ulf Schnetzke, Andreas Hochhaus, Sebastian Scholl
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	AML targeted therapy clinical trial resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/92d98bbe561a495e8ea86d12d1f69b9f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:92d98bbe561a495e8ea86d12d1f69b9f
record_format	dspace
spelling	oai:doaj.org-article:92d98bbe561a495e8ea86d12d1f69b9f2021-11-25T17:03:16ZManagement of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives10.3390/cancers132257222072-6694https://doaj.org/article/92d98bbe561a495e8ea86d12d1f69b9f2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5722https://doaj.org/toc/2072-6694Treatment of acute myeloid leukemia (AML) has improved in recent years and several new therapeutic options have been approved. Most of them include mutation-specific approaches (e.g., gilteritinib for AML patients with activating <i>FLT3</i> mutations), or are restricted to such defined AML subgroups, such as AML-MRC (AML with myeloid-related changes) or therapy-related AML (CPX-351). With this review, we aim to present a comprehensive overview of current AML therapy according to the evolved spectrum of recently approved treatment strategies. We address several aspects of combined epigenetic therapy with the BCL-2 inhibitor venetoclax and provide insight into mechanisms of resistance towards venetoclax-based regimens, and how primary or secondary resistance might be circumvented. Furthermore, a detailed overview on the current status of AML immunotherapy, describing promising concepts, is provided. This review focuses on clinically important aspects of current and future concepts of AML treatment, but will also present the molecular background of distinct targeted therapies, to understand the development and challenges of clinical trials ongoing in AML patients.Maximilian FleischmannUlf SchnetzkeAndreas HochhausSebastian SchollMDPI AGarticleAMLtargeted therapyclinical trialresistanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5722, p 5722 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	AML targeted therapy clinical trial resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	AML targeted therapy clinical trial resistance Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Maximilian Fleischmann Ulf Schnetzke Andreas Hochhaus Sebastian Scholl Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
description	Treatment of acute myeloid leukemia (AML) has improved in recent years and several new therapeutic options have been approved. Most of them include mutation-specific approaches (e.g., gilteritinib for AML patients with activating <i>FLT3</i> mutations), or are restricted to such defined AML subgroups, such as AML-MRC (AML with myeloid-related changes) or therapy-related AML (CPX-351). With this review, we aim to present a comprehensive overview of current AML therapy according to the evolved spectrum of recently approved treatment strategies. We address several aspects of combined epigenetic therapy with the BCL-2 inhibitor venetoclax and provide insight into mechanisms of resistance towards venetoclax-based regimens, and how primary or secondary resistance might be circumvented. Furthermore, a detailed overview on the current status of AML immunotherapy, describing promising concepts, is provided. This review focuses on clinically important aspects of current and future concepts of AML treatment, but will also present the molecular background of distinct targeted therapies, to understand the development and challenges of clinical trials ongoing in AML patients.
format	article
author	Maximilian Fleischmann Ulf Schnetzke Andreas Hochhaus Sebastian Scholl
author_facet	Maximilian Fleischmann Ulf Schnetzke Andreas Hochhaus Sebastian Scholl
author_sort	Maximilian Fleischmann
title	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
title_short	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
title_full	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
title_fullStr	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
title_full_unstemmed	Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
title_sort	management of acute myeloid leukemia: current treatment options and future perspectives
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/92d98bbe561a495e8ea86d12d1f69b9f
work_keys_str_mv	AT maximilianfleischmann managementofacutemyeloidleukemiacurrenttreatmentoptionsandfutureperspectives AT ulfschnetzke managementofacutemyeloidleukemiacurrenttreatmentoptionsandfutureperspectives AT andreashochhaus managementofacutemyeloidleukemiacurrenttreatmentoptionsandfutureperspectives AT sebastianscholl managementofacutemyeloidleukemiacurrenttreatmentoptionsandfutureperspectives
_version_	1718412789498773504

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives

Ejemplares similares